Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts

Abstract

Tamoxifen is a widely prescribed adjuvant anti-estrogen agent for estrogen receptor-positive breast cancer. Tamoxifen is known to undergo CYP2D6-mediated bioactivation to the active metabolite endoxifen. Endoxifen concentrations exhibit high interindividual variability, contributing to either sub-optimal tamoxifen efficacy or side effects in subsets of… (More)
DOI: 10.1007/s10549-013-2530-1

Topics

6 Figures and Tables

Cite this paper

@article{Gong2013DeterminationOC, title={Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts}, author={Inna Y. Gong and Wendy A. Teft and Justin Q. Ly and Yung-Hsiang Chen and Bruno Alicke and Richard B Kim and Edna F Choo}, journal={Breast Cancer Research and Treatment}, year={2013}, volume={139}, pages={61-69} }